Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

1.1K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.1K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

120
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
120
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

66
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
66
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

111
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
111
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

123
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
123
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anifrolumab induces a fast improvement in ultrasound-detected synovitis in systemic lupus erythematosus: Results from a 6-months follow-up ultrasound study.

Lupus·2026
Same author

Italian Olfactory Identification Test in Systemic Lupus Erythematosus: Association of Olfactory Impairment With Chronic Damage and Anti-β<sub>2</sub>-Glycoprotein I Antibodies.

ACR open rheumatology·2026
Same author

JAK inhibitors in areas outside of inflammatory arthritis: focus on connective tissue diseases.

Rheumatology (Oxford, England)·2026
Same author

Pre-test probability determines optimal ANA screening strategy: a risk-stratified comparison of indirect immunofluorescence and CTD screen assay.

Clinical chemistry and laboratory medicine·2026
Same author

Real-world effectiveness and safety of apremilast in psoriatic arthritis: results from the multicenter Italian MAPSI II study.

Clinical rheumatology·2026
Same author

Distinct molecular profile in Sjögren's syndrome is associated with disease activity and clinical manifestations.

Scientific reports·2026

Related Experiment Video

Updated: Nov 15, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.2K

Comprehensive disease control in systemic lupus erythematosus.

Fulvia Ceccarelli1, Giulio Olivieri1, Alessio Sortino2

  • 1Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Viale del Policlinico 155, 00161 Rome, Italy.

Seminars in Arthritis and Rheumatism
|March 2, 2021
PubMed
Summary
This summary is machine-generated.

Lupus comprehensive disease control (LupusCDC) effectively merges disease activity and damage in Systemic Lupus Erythematosus (SLE) patients. Achieving LupusCDC is linked to lower rates of renal involvement and immunosuppressant use, indicating better long-term outcomes.

Keywords:
Chronic damageComprehensive disease controlDisease activityMachine learning modelsRemissionSystemic lupus erythematosus

More Related Videos

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.3K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

358

Related Experiment Videos

Last Updated: Nov 15, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.2K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.3K
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

358

Area of Science:

  • Rheumatology
  • Immunology
  • Data Science in Medicine

Background:

  • Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by unpredictable flares and progressive organ damage.
  • Assessing comprehensive disease control in SLE is crucial for evaluating treatment efficacy and long-term prognosis.
  • Current metrics often evaluate disease activity and damage separately, potentially missing a holistic view of patient status.

Purpose of the Study:

  • To evaluate the frequency of Lupus comprehensive disease control (LupusCDC) in a monocentric cohort of SLE patients.
  • To define LupusCDC as the achievement of remission and absence of chronic damage progression over a 5-year follow-up.
  • To identify factors associated with achieving LupusCDC and explore predictive modeling using machine learning.

Main Methods:

  • A longitudinal analysis of 172 SLE patients with a 5-year follow-up was conducted.
  • Disease activity was assessed using SLE Disease Activity Index 2000 (SLEDAI-2K), and remission was defined by three levels (Complete Remission, clinical remission off-corticosteroids, clinical remission on-corticosteroids).
  • Chronic damage was measured by SLICC Damage Index (SDI). Machine learning models (SVM, DT) and ReliefF algorithm were used for analysis.

Main Results:

  • LupusCDC, including Complete Remission, was the most frequently detected state.
  • Failure to achieve LupusCDC was associated with renal involvement and the use of immunosuppressants and glucocorticoids (GC).
  • Ten patients (5.8%) maintained LupusCDC throughout the 5 years, showing no renal involvement and fewer anti-phospholipid antibodies. Machine learning models achieved AUC scores around 0.71.

Conclusions:

  • LupusCDC effectively integrates SLE disease activity and chronic damage assessment into a single outcome.
  • This comprehensive evaluation provides a more holistic view of SLE patient status.
  • The findings suggest that LupusCDC can be a valuable endpoint for assessing long-term disease control in SLE.